Skip to Main Content
Contribute Try STAT+ Today

Ruth Lehmann became director of the Whitehead Institute for Biomedical Research in July 2020. That juncture was deep enough into the pandemic for the research hub to be gradually reopening after a March 20 shutdown, but the center affiliated with nearby Massachusetts Institute of Technology is still adapting to life with Covid-19. The institute has improved air circulation, made entrances hands-free, added regular coronavirus testing for employees, and modified the cafeteria for in-house “takeout” meals. About 80% of scientists have returned to their labs to work in socially distanced shifts, administrative staff mostly work from home, and Lehmann spends much of her time in her institute office on Zoom calls.

A noted cell biologist who moved her lab from New York University to Cambridge, Mass., Lehmann promotes basic science as the driving force behind the extraordinary advances leading to rapidly developed Covid-19 vaccines. She also laments the toll the pandemic has taken on women in science. In a conversation with STAT, Lehmann charts the institute’s way forward, explains her own science, and shares two things people might not know about the Whitehead. This interview has been condensed and lightly edited.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.